Merck & Co., Inc. $MRK Shares Acquired by Diamant Asset Management Inc.

Diamant Asset Management Inc. boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 12,130.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,068,387 shares of the company’s stock after buying an additional 2,051,475 shares during the period. Merck & Co., Inc. accounts for 0.8% of Diamant Asset Management Inc.’s portfolio, making the stock its 23rd biggest holding. Diamant Asset Management Inc. owned about 0.08% of Merck & Co., Inc. worth $248,806,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. in the third quarter worth approximately $31,000. Finally, High Note Wealth LLC lifted its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRK. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Citigroup assumed coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Finally, UBS Group lifted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.72.

Merck & Co., Inc. Trading Up 2.3%

Merck & Co., Inc. stock opened at $128.35 on Friday. The firm has a market cap of $316.99 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 2.89 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $128.78. The firm’s 50 day moving average price is $116.08 and its two-hundred day moving average price is $114.33. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.’s payout ratio is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.